Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1439 results about "Fusion gene" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A fusion gene is a hybrid gene formed from two previously separate genes. It can occur as a result of: translocation, interstitial deletion, or chromosomal inversion.
SARS-CoV-2 vaccine and preparation method thereof
ActiveCN111217917AEnter to helpImproving immunogenicityPolypeptide with localisation/targeting motifSsRNA viruses positive-senseAntigenDisease
The invention relates to a preparation method for a vaccine capable of treating and / or preventing SARS-CoV-2 infection or COVID-19 diseases. The core antigen of the vaccine comprises the RBD (receptor binding zone) fusion protein of the SARS-CoV-2, and a vaccine form comprises an RBD fusion protein subunit vaccine, an RBD fusion protein mRNA vaccine or an RBD fusion protein adenovirus vector vaccine. The above vaccine immunizes an organism, and immune reaction for treating and / or preventing the SARS-CoV-2 infection can be generated so as to be used for treating and / or preventing COVID-19. The invention also relates to an RBD fusion gene, the RBD fusion protein, a carrier, a cell, a preparation method, a treatment method or a pharmacy purpose of the SARS-CoV-2.
Owner:CANSINO BIOLOGICS INC
Yeast-based therapeutic for chronic hepatitis C infection
InactiveUS7439042B2Reduces and prevents HCV infectionSsRNA viruses positive-senseViral antigen ingredientsChronic viral hepatitis CYeast
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.
Owner:GLOBE IMMUNE INC
Recombinant viruses displaying a nonviral polypeptide on their external surface
InactiveUS6297004B1Genetic material ingredientsImmunological disordersGene deliveryAntibody fragments
We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.
Owner:BIOFOCUS DICOVERY
KIAA1217-RET fusion gene
ActiveCN105255927AActivate kinase domain activityHigh expressionHybrid peptidesDNA/RNA fragmentationRet geneNucleotide
The invention discloses a KIAA1217-RET fusion gene. The KIAA1217-RET fusion gene is formed by exons from number one to number eleven of a KIAA1217 gene and exons from number eight to number nineteen of an RET gene in a fusion mode, and the nucleotide sequence is shown in figure 1. Disclose of the fusion gene is favorable for further study of drive genetic modification not found in thyroid cancer, and the clinical pathological classification and treatment strategies of patients suffering from papillary thyroid carcinoma are optimized.
Owner:THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV +3
Method for constructing chromosome translocation stem cell and animal model by CRISPR-Cas9 technology
The invention relates to a method for preparing a chromosome translocation stem cell model and an animal model. The method mainly comprises the steps of inducing occurrence of specific site chromosome translocation in stem cells by means of CRISPR / Cas9 technology, preparing a cell model and further constructing an animal model carrying the specific site chromosome translocation by utilizing embryonic stem cell technology. The method particularly comprises the steps of simultaneously introducing Cas9 and gRNA aiming at two target chromosome sites into the stem cells to artificially inducing chromosome dislocation of specific sites, and screening to obtain the cell model carrying the chromosome translocation. The animal model carrying chromosome translation of the specific sites can be further prepared from the chromosome translocation animal embryonic stem cells carrying chromosome translation by utilizing a chimera technology. The method has relatively large application prospect in studies on chromosome translocation and functions of fusion genes, researches on chromosome interaction and medicine screening evaluation.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Method for amplification and assay of RNA fusion gene variants, method of distinguishing same and related primers, probes, and kits
Method for amplification, alone or in further combination with detection or detection and quantitation, of RNA from fusion gene variants, method of distinguishing same, and oligonucleotide primers and probes and kits for use in the methods.
Owner:ABBOTT MOLECULAR INC A CORP ORGANISED & EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE
Genome editing method based on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) system and application thereof
ActiveCN107937432AImprove editing efficiencyImprove editing abilityHydrolasesVector-based foreign material introductionInteinFusion gene
Owner:HUAZHONG AGRI UNIV
Gene defects and mutant ALK kinase in human solid tumors
In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
Owner:CELL SIGNALING TECHNOLOGY
Yeast-based therapeutic for chronic hepatitis C infection
InactiveUS20060110755A1Reduces and prevents HCV infectionSsRNA viruses positive-senseViral antigen ingredientsChronic hepatitisYeast form
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.
Owner:GLOBE IMMUNE INC
Gene defects and mutant ALK kinase in human solid tumors
Owner:CELL SIGNALING TECHNOLOGY
Foot-and-mouth disease virus capsid protein tandem coexpressions and virus-like particle preparation method
ActiveCN104404074AHigh activityNatural binding activityBacteriaInactivation/attenuationEscherichia coliVirus-like particle
The invention relates to escherichia coli-derived single-plasmid-tandem soluble coexpression foot-and-mouth disease virus capsid proteins VP0 (which is a VP4 and VP2 fusion gene), VP1 and VP3, and a foot-and-mouth disease virus capsid protein virus-like particle preparation method. Foot-and-mouth disease virus capsid protein virus-like particles can be used for preparation of a foot-and-mouth disease vaccine. According to the method, a plurality of aspects of escherichia coli-derived soluble coexpression foot-and-mouth disease virus capsid protein are studied, by comprehensive use of tandem coexpression and SUMO(suggested upper merged ontology) technology with a tag for soluble coexpression of the foot-and-mouth disease virus capsid proteins VP0 (which is the VP4 and VP2 fusion gene), VP1 and VP3, the ultimate objective protein accounts for about 20% of total bacterial protein, and the foot-and-mouth disease virus capsid proteins obtained by purification can be successfully assembled into the virus like particles.
Owner:SA BIOTECH (SUZHOU) PTE LTD
Method for biosynthesis preparation of human GLP-1 polypeptide or analogue thereof
InactiveCN106434717AEasy to separateHigh expressionNucleic acid vectorFusion with protease siteEscherichia coliEnzyme digestion
The invention relates to a method for biosynthesis preparation of human glucagon-like peptide-1 (GLP-1) and an analogue thereof. With adopting of a gene engineering technology, a recombinant escherichia coli expressed GLP-1 fusion protein is constructed, and a protein enzyme digestion site is designed in the fusion protein; a fusion gene has a gene sequence with a form of A-B-C structure, wherein A is a chaperonin gene, B is a nucleotide sequence encoding a connection peptide containing the enzyme digestion site, and C is a gene encoding the GLP-1 or the analogue thereof. After recombinant engineering bacteria is subjected to induced expression, the fusion protein is purified and subjected to enzyme digestion, and then the GLP-1 and the analogue thereof are obtained and are detected to have biological activity. The preparation method of the GLP-1 and the analogue thereof provided by the invention is simple and quick, the production conditions are mild, the product is convenient to separate and extract, the process is simple, and the industrialization prospect is good.
Owner:HANGZHOU JIUYUAN GENE ENG +1
Method for preparing recombinant glossy ganoderma immunomodulatory protein
InactiveCN101205553AControl overproliferationSimple process conditionsPowder deliveryFungiPichia pastorisGlycerol
The invention provides a preparing method of reconstructing immunoregulatory protein of a ganoderma lucidum. The method includes the following steps: construction of engineering bacteria, wherein, LZ-8 protein gene is designed and coded, and is connected with a leading peptide coding sequence of saccharomyces cervisiae alpha-factor into fusion gene, which is transferred to a Pichia Pastoris expression system GS115 for reconstructing expression, high expressed rLZ-8 protein bacterial strain is acquired; the fermentation under the scale of 100L fermentation cylinder, wherein, improved seed culture medium and fermentation medium are used, additions of glycerol and methanol are regulated, 0.5M(NH4)2SO4 is added at the late stage of the fermentation; the purification on a column via centrifugal separation, wherein, salt is hyperfiltrated, powder is prepared after being frozen and dried. The method has large scale of fermentation, optimized technological condition and high production rate.
Owner:张喜田
Probe and sequence combination for simultaneous detection of various mutation types
InactiveCN106480205ARealize multiple comprehensive detectionAccurate detectionMicrobiological testing/measurementDNA/RNA fragmentationHydrothoraxTherapeutic effect
The invention discloses a probe and a sequence combination for simultaneous detection of various mutation types and particularly provides a kit, a method, a gene chip, a probe and a sequence combination which are high in sensitivity and specificity and used for simultaneous detection of point mutation, short segment insertion and deletion, copy number variation and fusion genes of 57 tumor driver genes listed in a detection list. The invention further discloses a sequence combination and probe associated gene chip and kit and a method for simultaneous detection of various mutation types. By detection of body fluid including blood, hydrothorax, abdominal dropsy and the like and tumor frozen tissues or paraffin sections, comprehensive tumor driver gene mutation information can be acquired, sensitivity and accuracy in tumor gene detection are improved, and accordingly clinicians can be assisted in making of individualized medication schemes to achieve best accurate treatment effects.
Owner:BEIJING GENEPLUS TECH +1
Zoophobous fusion protein and use thereof
ActiveCN1818067ABroad insecticidal spectrumHigh insecticidal rateFermentationHybrid peptidesOpen reading frameNucleotide
The invention opened an antiworm fusion gene which includes the nucleotides sequence with encoding the BT crystalline toxin and the Vip3 toxin from 5'-3'. The two sequences are in the same open reading frame. The BT crystalline toxin is the whole long or the active toxin without C end. The invention also opened the use of the fusion gene in the antiworm plants.
Owner:沈志成
Yeast-based therapeutic for chronic hepatitis c infection
InactiveUS20080069831A1Reduces and prevents HCV infectionBiocideSsRNA viruses positive-senseChronic hepatitisYeast form
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.
Owner:GLOBE IMMUNE INC
Primers, probes, detection system and kit for one time detection of lung cancer multiple genes
ActiveCN104818320AWill not interfere with each otherLow costMicrobiological testing/measurementDNA/RNA fragmentationTumor targetBRAF Gene Mutation
The present invention discloses primers, probes, a detection system and a kit for one time detection of lung cancer multiple genes, wherein the primers, the probes, and the distribution way for detecting 25 EGFR gene mutations, 7 KRAS gene mutations, 6 BRAF gene mutations, 9 NRAS gene mutations, 5 HER2 gene mutations, 2 PIK3CA gene mutations, 5 fusion genes of ALK5, 13 fusion genes of ROS1, and 6 fusion genes of RET are provided. According to the present invention, the detection kit adopts the 12 linking PCR reaction strip design, each 12 linking PCR strip detects multiple genes of a sample, and the corresponding fusion detection reagents and the internal control reagents are filled in the pipes 1-4 of the 12 linking PCR strip; and with the primers, the probes, the detection system and the kit, the one-time detection of the 24 fusions and the 54 mutations of the lung cancer can be achieved, such that the detection time is substantially shortened, the sensitivity is high, the specificity is strong, the operation is simple and rapid, and the reference for selection of tumor targeting drug therapy on lung cancer patients can be provided for clinician.
Owner:AMOY DIAGNOSTICS CO LTD
Hepatitis C virus non-structural NS3/4A fusion gene
InactiveUS6960569B2Enhance and facilitate immune responseOrganic active ingredientsVirusesHuman patientFusion gene
Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the inevntion include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
Owner:TRIPEP
Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe
ActiveCN102827937ADiagnosis helpsHelp to getMicrobiological testing/measurementDNA/RNA fragmentationGenotypeClinical diagnosis
The invention relates to detection of genotypes, in particular to a primer and a probe for detecting relative fusion genes of leukemia and a kit of the primer and the probe. The kit can qualitatively detect quantity of BCR-ABL, AML1-ETO and PML-RARa of the relative fusion genes of the leukemia in human marrow specimens so as to instruct clinical diagnosis and pharmacy of the leukemia.
Owner:上海源奇生物医药科技有限公司
Pathogenic microorganism genome database and establishment method thereof
ActiveCN110473594AReduce data volumeAvoid false positivesBioinformaticsInstrumentsPathogenic microorganismHemidesmosome assembly
The invention relates to a pathogenic microorganism genome database and an establishment method thereof, and belongs to the technical field of meta-genomes. The method comprises the following steps ofdata acquisition, wherein pathogenic microorganism genome data is obtained; strain genome screening, wherein species strain genomes are selected according to a predetermined screening rule; plasmid sequence removal, wherein plasmid sequences existing in the strain genomes obtained in the last step are removed; filtration, wherein according to a predetermined filtering rule, strains with incorrectlabeling information, incomplete chromosome assembly and incorrect classification are removed to obtain a reference strain genome of the species; fusion genome construction, wherein the reference strain genome is interrupted, redundancy is removed, reassembly is performed, and the sequences are reassembled to obtain a fusion genome of the species; database assembly, wherein the above steps are repeated to obtain the fusion genome of the predetermined species, summary is performed, and the pathogenic microorganism genome database is obtained. The genome database has the advantages of not onlyhaving a high precision rate, but also having short analysis time and reducing the cost.
Owner:GZ VISION GENE TECH CO LTD +4
Method and device for detecting gene fusion
ActiveCN104894271AHigh sensitivityStrong specificityBioreactor/fermenter combinationsBiological substance pretreatmentsComputer scienceFusion gene
The invention discloses a method and a device for detecting gene fusion, wherein the method comprises the following steps: S1, extracting RNA of a to-be-detected sample, and performing reverse transcription on RNA to obtain cDNA; S2, designing primers on two sides of a breaking point of a known fusion gene, and taking cDNA as a template for amplifying to form a sequence with a fusion form, and establishing a sequencing library; S3, sequencing the sequencing library by a high-throughput method to obtain a sequence with a fusion form; S4, detecting the sequence with the fusion form, particularly, S41, using comparison software to compare the sequence with the fusion form, obtained from the step 3, with a corresponding reference sequence with the fusion form; S42, judging whether data obtained from the step S41 meet the analysis requirements or not; S43, detecting the known fusion forms. The method has the advantages of being high in sensitivity and specificity and relatively economic.
Owner:天津诺禾致源生物信息科技有限公司
Transcriptome-based tumor neoantigen identification method
ActiveCN108491689AImprove accuracyComprehensive identificationSequence analysisSpecial data processing applicationsSample sequenceTumor-specific antigen
The invention discloses a transcriptome-based tumor antigen identification method. The method comprises four steps of: obtaining an RNA sample of a patient tumor tissue, and carrying out library construction and amplification on the RNA sample to obtain an RNA sample sequencing result of the tumor tissue; aligning short read segments of the RNA sample sequencing result to a human reference genometo obtain an RNA alignment result; calculating gene expression quantity according to the RNA alignment result, and carrying out mutation detection and prediction of fusion gene events according to theRNA alignment result; and predicting transcriptome HLA typing according to the alignment result, wherein calculation of the gene expression quantity, mutation detection and prediction of the fusion gene events are carried out according to a specified order or simultaneously carried out; and using the gene expression quantity of a transcriptome sample, depth of transcriptome mutation sites in a whole-exon sequencing sample and binding force of neonatal short peptides and the patient HLA typing as an analysis result to submit the same to a downstream analyst. The invention provides the method capable of identifying a tumor-specific antigen of an individual sample from tumor patient transcriptome NGS data.
Owner:HANGZHOU NEOANTIGEN THERAPEUTICS CO LTD
Insect-fusion-resistant gene, coding protein, carrier and application thereof
InactiveCN105624177AHigh insecticidal activityBroad insecticidal spectrumAntibody mimetics/scaffoldsHybrid peptidesResistant genesCotton bollworm
The invention discloses an insect-fusion-resistant gene, coding protein, a carrier and application thereof. The insect-fusion-resistant gene is formed by using a connecting peptide coding gene to connect a nucleotide sequence of coding BT insecticidal crystal protein Cry1Ab with coding BT trophophase insecticidal protein Vip3A, the connecting peptide amino acid sequence is shown as SEQ ID NO:1. Insecticidal activity of the insect-fusion-resistant gene is improved, and insecticidal spectrum is wider. The insect-fusion-resistant gene can kill main lepidopterous insects like armyworm, Spodoptera litura, Ostrinia furnacalis, cotton bollworm and Spodoptera exigua of paddy and maize. In addition, the insect-fusion-resistant gene can effectively slow down insect resistance.
Owner:ZHEJIANG UNIV
EML4-ALK (Echinoderm microtubule associated protein like4-anaplastic lymphoma kinase) fusion gene fluorescent quantitative PCR (polymerase chain reaction) assay kit
ActiveCN103468813AEliminate distractionsHigh detection sensitivityMicrobiological testing/measurementEchinodermConserved sequence
The invention relates to an EML4-ALK (echinoderm microtubule associated protein like4-anaplastic lymphoma kinase) fusion gene fluorescent quantitative PCR (polymerase chain reaction) assay kit, which is applicable to assay of EML4-ALK fusion gene mutation in lung adenocarcinoma. The kit comprises probes, primers and positive controls, which are specially designed for conserved sequences of 9 fusion variations of the EML4-ALK fusion gene. The kit can be used for quickly and accurately assaying 9 most common EML4-ALK fusion gene variations with high sensitivity, namely 9 fusion variations of 7 variant subtypes, which are subtype 1 (E13; A20), subtype 2 (E20; A20), subtype 3 (E6a / b; A20), subtype 4 (E14; A20), subtype 5 (E2a / b; A20), subtype 6 (E18; A20) and subtype 7 (E14; A20), so that a real-time fluorescent quantitative PCR system for assaying 9 most common EML4-ALK fusion gene variations can be established.
Owner:广州达健生物科技有限公司
Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
Owner:ALNYLAM PHARMA INC
Method for detecting off-target effect of adenine base editor system based on whole genome sequencing, and its application in gene editing
PendingCN109295186AAccelerate cultivationMicrobiological testing/measurementAgainst vector-borne diseasesGenome editingWhole genome sequencing
The invention provides a method for detecting the off-target effect of an adenine base editor system based on whole genome sequencing, and its application in gene editing, The adenine base editor system comprises a TadA:TadA*:Cas9 fusion gene and gRNA. The system can catalyze the efficient replacement of adenine (A) at a target site with guanine (G), and has a broad application prospect in human disease gene editing therapy and disease model construction. The first method for detecting the off-target effect of the ABE system in a whole genome range, called EndoV-seq method for short, is developed in the invention. The EndoV-seq method provided by the invention has a broad application prospect in the field of gene editing, especially gene editing therapy.
Owner:SUN YAT SEN UNIV
NGF-Fc fusion protein and preparation method thereof
InactiveCN105273087AImprove stabilityExtended half-lifeNervous disorderPeptide/protein ingredientsDiseaseNervous system
The invention belongs to the technical field of biological engineering, and relates to an NGF-Fc fusion protein and a preparation method thereof. The method comprises the following steps: constructing a human immune globulin IgG Fc and nerve growth factor (NGF) fusion gene expression vector through a genetic engineering means, transferring to a mammal cell to make the transferred mammal cell highly express and produce NGF-Fc fusion proteins, purifying, identifying and carrying out biological activity detection. The expression vector transferred mammal cell constructed in the invention can express bioactive NGF-Fc fusion proteins, so the expression level can be 150mg / L or above, and the obtained protein has good stability and long half life, and can be used to prepare drugs for treating Alzheimer's disease, diabetic peripheral neuropathy, Parkinson's disease, facial neuritis, craniocerebral trauma, trauma of spinal cord, acute cerebrovascular disease, encephalatrophy and other neurological diseases, and peripheral nerve injury acute cerebral vascular central nerve injuries induced by chemical drugs.
Owner:FUDAN UNIV
Leukemia fusion gene combined parallel detecting method and diagnostic reagent kit
InactiveCN101838682AHigh sensitivityStrong specificityMicrobiological testing/measurementFluorescence/phosphorescenceBiotin-streptavidin complexFluorescence
The invention discloses a leukemia fusion gene combined parallel detecting method and a diagnostic reagent kit. The combined parallel detecting method is characterized in that multiple fusion genes related to leukemia can be detected at one time. By designing a primer and a probe of the leukemia fusion gene mRNA, the mixture covalently combined by the probe and microspheres is hybridized with a reverse transcription PCR amplified product, the streptavidin of phycoerythrin is added, and then the fluorescence signals of different microspheres can be detected, thereby determining whether the sample to be detected contains leukemia fusion genes or not and the express conditions of the fusion genes. The diagnostic reagent kit has the advantages of high sensitivity, high flux property, quick and accurate detection, and the like, and can simultaneously carry out qualitative and quantitative detection on multiple leukemia fusion genes.
Owner:MEDI GENETECH
Electrochemical sensor and its prepn process and use
InactiveCN101046461AHigh mutation rateStrong specificityMicrobiological testing/measurementMaterial analysis by electric/magnetic meansCarboxyl radicalCarbon nanotube
The present invention discloses one kind of electrochemical sensor and its preparation process and use. The electrochemical sensor is prepared through decorating the surface of glass-carbon electrode with open-mouthed multi-wall carbon nanotube possessing carboxylated end, fixing BCR / ABL b3-a2 type gene probe through covalent decoration onto the end carboxyl radical of carbon nanotube, hybridizing the probe DNA and the target DNA and adopting curcumin as hybridization indicator for researching the recognizing capacity of single strand fixed on the decorated electrode on complementary DNA. The carbon nanotube has great specific surface area favoring the fixing of DNA on the electrode and excellent electron transferring characteristic for high detection sensitivity of sensor. The sensor is used in detecting chronic granulocytic leukemia gene and has high selectivity and high sensitivity.
Owner:FUJIAN MEDICAL UNIV
Gene defect and mutant ALK kinase in human entity tumour
ActiveCN101466721APeptide/protein ingredientsAntibody mimetics/scaffoldsADAMTS ProteinsProtein translocation
In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule- Associated Protein-Like 4 (EML-4) and TRK- Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
Owner:CELL SIGNALING TECHNOLOGY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com